Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal botulinum toxin type A for refractory rhinitis
ACTRN12625001411437Phase 2Not yet recruiting
- Sponsor
- Metro North Health
- Start
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of botulinum toxin type A in allergic rhinitis (AR) and non-allergic rhinitis (NAR) (2 arms), sponsored by Metro North Health. Primary endpoint: Change in Total Nasal Symptom Score. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
allergic rhinitis (AR)non-allergic rhinitis (NAR)
Beyond the preview
Go deeper on ACTRN12625001411437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001411437.